SEC filings and other documents

Promising phase II diabetes results and next-gen GLP-1 data set for major readouts this year.

Novel oral therapies show promise for diabetes and obesity with key Phase II data ahead.

Net loss narrowed and clinical trial progress supports cash runway into Q2 2027.

Icovamenib and BMF-650 show promise for durable diabetes and obesity treatment innovation.

Directors and auditors were approved by majority vote, with results to be filed with the SEC.

Phase II diabetes and obesity trials advance, with key data expected in the next 12 months.

Icovamenib and BMF-650 show promise for durable diabetes and obesity treatment breakthroughs.

Icovamenib and BMF-650 advance in trials, targeting diabetes and obesity with novel mechanisms.

Clinical progress and reduced losses position the pipeline for key 2026 milestones.

Icovamenib offers durable glycemic control and beta cell regeneration in diabetes.

Icovamenib boosted C-peptide by 52% at 12 weeks and preserved beta cell function at 1 year.

Oral therapies icovamenib and BMF-650 advance toward major diabetes and obesity milestones.

Icova­menib may transform diabetes care by restoring beta cell function and delaying insulin use.

Imminent clinical data for BMF-650 and icovamenib target major advances in obesity and diabetes.

Novel diabetes and obesity therapies show durable efficacy, with pivotal data expected in 2024.

Icovamenib and BMF-650 advance in trials, targeting unmet needs in diabetes and weight loss.

Oral therapies show durable diabetes control and robust preclinical weight loss, with pivotal data ahead.

Durable A1C reduction and weight loss assets advance, with pivotal data and strong cash runway ahead.

Icovamenib and BMF-650 offer durable, disease-modifying oral therapies for diabetes and obesity.

Clinical progress in diabetes and obesity, reduced net loss, and strong cash position into 2027.

Advancing Menin and oral GLP-1 therapies for diabetes, with phase II trials and strong financial runway.

Promising diabetes therapies advance with pivotal data and partnership-driven development ahead.

Icovamenib delivers durable HbA1c reduction after short-term dosing in severe T2D.